



Postgraduate Institute  
for Medicine



*A Satellite Symposium held in  
SAN ANTONIO, TEXAS*

# COURT OF ONCOLOGY OPINION

FRIDAY, DECEMBER 12, 2008  
7:30 PM-9:30 PM

DINNER WILL BE SERVED

*© M. Loran*



GRAND HYATT SAN ANTONIO  
Texas Ballroom, Salons D & E  
4th Floor, 600 East Market Street  
San Antonio, TX

Cut off

## STATEMENT OF NEED:

Significant improvements have occurred in the management of breast cancer over the past decade. One of the most widely studied approaches in the field of cancer, particularly breast cancer, is personalized treatment strategies incorporating gene array profiles, new agents and novel combinations. Despite these advances, uncertainties remain. With novel pharmacological agents, diagnostic and treatment strategies, the decision-making process is challenging, thereby requiring in-depth knowledge of current clinical and experimental data for the appropriate integration of new treatment strategies into clinical practice. Because of this, healthcare professionals caring for patients with breast cancer need to understand the basis for treatment approaches likely to change clinical practice in the next few years, as well as the preclinical and clinical data supporting the development and integration of these therapies into practice.

### Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and PRIME Oncology. PIM is accredited by the ACCME to provide continuing medical education for physicians.

### Credit Designation Statement

PIM designates this educational activity for a maximum of **2.0 AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.



### Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Kim Friese prior to the live event at (678) 892-1340 or kim.friese@primeoncology.org.

## TARGET AUDIENCE

This educational activity is intended for medical, surgical, and radiation oncologists, as well as allied oncology healthcare professionals who treat patients with breast cancer.

## FACULTY

### LARRY NORTON, MD

(CO-CHAIR)

Deputy Physician-in-Chief  
Director, Breast Cancer Programs  
Memorial Sloan-Kettering Cancer Center  
New York, New York, USA

### MARTINE PICCART-GEBHART, MD, PHD

(CO-CHAIR)

Professor of Oncology  
Université Libre de Bruxelles  
Head, Medicine Department  
Jules Bordet Institute  
Brussels, Belgium

### JOSÉ BASELGA, MD

Professor of Medicine  
Universidad Autonoma de Barcelona  
Chairman, Medical Oncology Service  
Director, Division of Medical Oncology, Hematology,  
and Radiation Oncology  
Vall d'Hebron University Hospital  
Barcelona, Spain

### LORI GOLDSTEIN, MD

Director, Breast Evaluation Center  
Leader, Breast Cancer Research Program  
Fox Chase Cancer Center  
Philadelphia, Pennsylvania, USA

### WILLIAM GRADISHAR, MD, FACP

Professor of Medicine  
Director, Breast Medical Oncology  
Program Director, Hematology/Oncology Fellowship  
Robert H. Lurie Comprehensive Cancer Center  
Northwestern University Feinberg School of Medicine  
Chicago, Illinois, USA

### NADIA HARBECK, MD

Associate Professor  
Department of Obstetrics and Gynecology  
Technical University of Munich  
Munich, Germany

### CLIFF HUDIS, MD

Professor of Medicine  
Weill Cornell College of Medicine  
Chief, Breast Cancer Medicine Service  
Memorial Sloan-Kettering Cancer Center  
New York, New York, USA

### HOPE RUGO, MD

Clinical Professor of Medicine  
Division of Hematology & Oncology  
Director, Breast Cancer Clinical Trials Program  
University of California San Francisco  
San Francisco, California, USA

### GEORGE W. SLEDGE, JR, MD

Ballve-Lantero Professor of Medicine  
Professor of Medicine and Pathology  
Co-Director Breast Oncology Program  
Chair, Breast Committee  
Eastern Cooperative Oncology Group  
Indiana University Simon Cancer Center  
Indianapolis, Indiana, USA

### MICHAEL UNTCH, MD

Professor of Gynecology, Gynecologic Oncology  
Director of Breast Cancer Center  
HELIOS Klinikum Berlin-Buch  
Berlin, Germany

## DOCKET

2.0 AMA PRA  
CATEGORY 1  
CREDITS

7:30 pm-7:40 pm .....Registration and Dinner  
Welcome and Introduction

LARRY NORTON, MD & MARTINE PICCART-GEBHART, MD, PHD

7:40 pm-8:05 pm .....Case #1: Management of Early Endocrine Responsive  
Postmenopausal Breast Cancer in the Near Future Will Include Upfront Extended  
Duration (>5 years) Adjuvant Aromatase Inhibitor Therapy and Adjuvant Use of a  
Bisphosphonate

PRO: WILLIAM GRADISHAR, MD, FACP

CONTRA: NADIA HARBECK, MD

8:05 pm-8:30 pm .....Case #2: Optimal Treatment of HER-2 Amplified Metastatic  
Breast Cancer Following Response to First Line Trastuzumab-based Therapy Should Be  
Rechallenge With a Trastuzumab-based Regimen

PRO: CLIFF HUDIS, MD

CONTRA: MICHAEL UNTCH, MD

8:30 pm-8:55 pm .....Case #3: Current Management of Triple Negative Breast  
Cancer Should Include an Angiogenesis Inhibitor

PRO: GEORGE SLEDGE, MD

CONTRA: JOSÉ BASELGA, MD

8:55 pm-9:20 pm .....Case #4: Risk Assessment and Treatment Planning for a  
Small Endocrine Responsive Node Positive Early Breast Cancer Should Include a Gene  
Array Profile Analysis

PRO: LORI GOLDSTEIN, MD

CONTRA: HOPE RUGO, MD

9:20 pm-9:30 pm .....“Judges” Closing Remarks and “Summation of Verdicts”  
LARRY NORTON, MD & MARTINE PICCART-GEBHART, MD, PHD

### Disclosure of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Cut off



# COURT OF ONCOLOGY OPINION

Friday, December 12, 2008 • Grand Hyatt San Antonio

## Register online at [www.primeoncology.org](http://www.primeoncology.org)

Pre-registration is not required for this event, however space is limited.

**Educational Objectives:** Upon completion of this educational activity, participants should be better able to:

- Describe rationale for the development and use of new therapeutic and individualized approaches to breast cancer
- Indicate the clinical implications of the results of pivotal clinical trials, including early phase trials, that have the potential to impact the use of therapies in breast cancer
- Identify potential treatment strategies and ongoing clinical trial designs for incorporating new treatment regimens in the treatment of breast cancer
- Cite data regarding the safety profiles of therapeutic approaches in the treatment of breast cancer, either alone or in combination with currently accepted standard therapies
- Identify methods for side effect management and maintenance of quality of life
- Compare novel therapies and/or regimens that provide the best patient outcomes including whether current guidelines provide similar recommendations
- Compare clinical outcomes and endpoints in order to establish which clinical trials are the most meaningful in improving patient care
- Identify optimal treatment regimens for patients with resistant metastatic breast cancer and triple negative disease
- Distinguish currently available prognostic and predictive tools to guide in treatment management of breast cancer patients